{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:40:11Z","timestamp":1758861611252,"version":"3.44.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gallbladder carcinoma (GBC) is a highly aggressive malignancy with limited treatment options and poor prognosis, particularly in advanced stages. Traditional chemotherapy often yields modest outcomes and can be poorly tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We report a case of a 59-year-old woman with stage IVA GBC who was unable to tolerate first-line gemcitabine and cisplatin due to severe adverse effects. Next-generation sequencing revealed a moderate tumor mutation burden and microsatellite-stable status. Based on a multidisciplinary team assessment, she received camrelizumab (PD-1 inhibitor) plus apatinib (VEGFR2 inhibitor).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 11 cycles, imaging demonstrated significant tumor regression and reduced invasion, enabling successful radical resection. Postoperative pathology confirmed moderately differentiated adenocarcinoma with no lymph node involvement. The patient remained disease-free for over two years. Following isolated cervical lymph node metastasis, combination therapy with camrelizumab and surufatinib resulted in complete remission. She continues on maintenance immunotherapy without recurrence five years post-diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case highlights the promising potential of targeted therapy and immunotherapy in converting unresectable GBC to operable disease and achieving durable remission, even in patients lacking classic immunotherapy biomarkers. Personalized, non-chemotherapy-based strategies may offer viable alternatives for selected patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1629985","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:12:40Z","timestamp":1758859960000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term survival after targeted therapy plus immunotherapy without chemotherapy in advanced gallbladder carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhitao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangjun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet (London England)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla","year":"2019","journal-title":"Clin Exp hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":":547","DOI":"10.3390\/cancers13030547","article-title":"Validation of the 8th edition american joint commission on cancer (AJCC) gallbladder cancer staging system: prognostic discrimination and identification of key predictive factors","volume":"13","author":"Giannis","year":"2021","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.12129","article-title":"Annual report of Japanese biliary tract cancer registry from 2021: Focus on the rate of R0 resection, postoperative complications, and site of lymph node metastasis","volume":"32","author":"Kato","year":"2025","journal-title":"J hepato-biliary-pancreatic Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2025.03.149","article-title":"Optimizing outcomes in gallbladder cancer: identifying predictors of futile up-front surgery in a global multi-center study","volume":"32","author":"Serenari","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv213","article-title":"Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT)","volume":"46","author":"Mizusawa","year":"2016","journal-title":"Japanese J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J hepato-biliary-pancreatic Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.019","article-title":"Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study","volume":"83","author":"Yoo","year":"2025","journal-title":"J hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40792-018-0512-6","article-title":"Long-term survival of a patient with recurrent gallbladder carcinoma, treated with chemotherapy, immunotherapy, and surgery: a case report","volume":"4","author":"Kawamoto","year":"2018","journal-title":"Surg Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","article-title":"Overview of current targeted therapy in gallbladder cancer","volume":"5","author":"Song","year":"2020","journal-title":"Signal transduction targeted Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100041","DOI":"10.1016\/j.xinn.2020.100041","article-title":"Current status and future perspective of immunotherapy in gastrointestinal cancers","volume":"1","author":"Lu","year":"2020","journal-title":"Innovation (Cambridge (Mass))"},{"key":"B15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal transduction targeted Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001240","article-title":"Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1533033820979703","DOI":"10.1177\/1533033820979703","article-title":"Experience with anti-PD-1 antibody, camrelizumab, monotherapy for biliary tract cancer patients and literature review","volume":"19","author":"Shen","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"Cd011746","DOI":"10.1002\/14651858.CD011746.pub2","article-title":"Gemcitabine-based chemotherapy for advanced biliary tract carcinomas","volume":"4","author":"Abdel-Rahman","year":"2018","journal-title":"Cochrane Database systematic Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-020-02031-5","article-title":"Conversion surgery for initially unresectable biliary Malignancies: a multicenter retrospective cohort study","volume":"50","author":"Noji","year":"2020","journal-title":"Surg Today"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1006075","article-title":"PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series","volume":"12","author":"Tan","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S427942","article-title":"Safety and efficacy analysis of PD-1 inhibitors in combination with gemcitabine plus nab-paclitaxel for advanced pancreatic cancer: A real-world, single-center study","volume":"16","author":"Chen","year":"2023","journal-title":"OncoTargets Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12876-025-03688-3","article-title":"PD-1 inhibitor combined with chemotherapy or lenvatinib in advanced gallbladder cancer: a retrospective comparative study","volume":"25","author":"Ma","year":"2025","journal-title":"BMC gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21203\/rs.2.22587\/v1","article-title":"Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study","volume":"8","author":"Feng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15641","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data","volume":"43","author":"Rimini","year":"2023","journal-title":"Liver Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s00262-024-03831-1","article-title":"Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer","volume":"73","author":"Tan","year":"2024","journal-title":"Cancer immunology immunotherapy: CII"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S208926","article-title":"Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report","volume":"12","author":"Kong","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.14701\/ahbps.2019.23.4.403","article-title":"Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection","volume":"23","author":"Prieto","year":"2019","journal-title":"Ann hepato-biliary-pancreatic surgery"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2020.04.25","article-title":"PD-L1 for gallbladder cancer: case report","volume":"9","author":"Li","year":"2020","journal-title":"Trans Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.21037\/atm-20-4420","article-title":"Complete response to immunotherapy combined with an antiangiogenic agent in multiple hepatic metastases after radical surgery for advanced gallbladder cancer: a case report","volume":"8","author":"Rao","year":"2020","journal-title":"Ann Trans Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbab017","article-title":"A case report of response to crizotinib in chemotherapy-refractory metastatic gallbladder cancer with met amplification and acquired resistance resulting from the loss of MET amplification","volume":"4","author":"Sun","year":"2021","journal-title":"Precis Clin Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"rjab414","DOI":"10.1093\/jscr\/rjab414","article-title":"A case from the future of HPB surgical oncology: resection of biliary tract cancer after immunotherapy","volume":"2021","author":"Satyananda","year":"2021","journal-title":"J Surg Case Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.818626","article-title":"Camrelizumab combined with gemcitabine and albumin-bound paclitaxel for neoadjuvant therapy in the treatment of progressive gallbladder cancer: A case report","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.820566","article-title":"Case report: durable complete response after combined immunotherapy following resection of primary tumor in a gallbladder cancer patient with distant metastatic lymph nodes of favorable immune-microenvironment","volume":"13","author":"Yi","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S346635","article-title":"Successful treatment of metastatic gallbladder carcinoma with PD-L1 expression by the combination of PD-1 inhibitor plus bevacizumab with chemotherapy: A case report","volume":"15","author":"Guo","year":"2022","journal-title":"OncoTargets Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.784861","article-title":"Case report: addition of PD-1 antibody camrelizumab overcame resistance to trastuzumab plus chemotherapy in a HER2-positive, metastatic gallbladder cancer patient","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-255403","article-title":"PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer","volume":"16","author":"Zhang","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04126-7","article-title":"Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: a case series and review of current literature","volume":"149","author":"Wang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1144371","article-title":"Case report: Preliminary response to tislelizumab plus S-1 in patients with metastatic gallbladder carcinoma: A report of five cases and a literature review","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1173520","article-title":"Case Report: Complete pathological remission of human chorionic gonadotrophin-producing gallbladder carcinoma with multiple liver metastases after treatment with chemotherapy plus an immune checkpoint inhibitor","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1353430","article-title":"Case report: From palliative to potentially curative - the advent of immunotherapy providing hope to advanced gallbladder adenocarcinoma","volume":"15","author":"Leong","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.21037\/acr-23-188","article-title":"Advanced gallbladder cancer with high tumor mutation burden: a case report and literature review","volume":"8","author":"Wang","year":"2024","journal-title":"AME Case Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002206","article-title":"Comprehensive treatment of gallbladder cancer: a case report","volume":"86","author":"Cui","year":"2024","journal-title":"Ann Med Surg (2012)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3892\/ol.2024.14606","article-title":"Evolving approaches in advanced gallbladder cancer with complete pathological response using chemo\u2212immunotherapy: A case report","volume":"28","author":"Orlandi","year":"2024","journal-title":"Oncol letters"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-024-02053-3","article-title":"A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin","volume":"18","author":"Araki","year":"2025","journal-title":"Clin J gastroenterology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"98433","DOI":"10.4251\/wjgo.v17.i1.98433","article-title":"Complete response of gallbladder cancer treated with gemcitabine and cisplatin chemotherapy combined with durvalumab: A case report and review of literature","volume":"17","author":"Chen","year":"2025","journal-title":"World J gastrointestinal Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1629985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:12:42Z","timestamp":1758859962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1629985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2025.1629985"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1629985","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"article-number":"1629985"}}